Business3 months ago
Mesoblast Reports 60% Surge in Ryoncil Sales for December Quarter
Australian biotechnology firm Mesoblast has announced a significant increase in sales of its cell therapy, Ryoncil, which achieved gross revenue of $35.1 million during the December...